📚 Academic Pearls & Indian Clinical Context
1. How the HbA1c Target Is Individualised
This engine does not apply a flat "7% for all" approach. It synthesises a target from four clinical parameters. The table below shows the exact logic used.
💡 Over-Control is Harm: If a patient on SU or insulin has HbA1c well below target (e.g. 5% against a target of 8%), this is NOT good control. It means recurrent hypoglycaemia. The engine flags this as a de-escalation trigger.
2. The HbA1c Reliability Trap
HbA1c accuracy depends on a normal RBC lifespan of ~120 days. In India, the massive prevalence of Iron Deficiency Anaemia and regional haemoglobinopathies frequently renders HbA1c dangerously misleading.
3. Dangerous Drug Combinations the Engine Flags
4. SGLT2i: Beyond Glucose Control
⚠ Mycotic Infection Risk: SGLT2i induce glycosuria. In Indian hot/humid climate, prescribing without strict counselling on genital hygiene causes severe mycotic balanoposthitis or vulvovaginitis.
Euglycaemic DKA: Withhold SGLT2i during acute illness, starvation, or 3 days before major surgery. Educate patients to seek urgent care for nausea/vomiting/abdominal pain even with normal glucose.
💡 Organ Protection: Dapagliflozin and Empagliflozin are now approved for HF and CKD even without diabetes (DAPA-HF, EMPEROR-Reduced/Preserved, DAPA-CKD). Every T2DM patient with ASCVD, HF, or CKD should be on an SGLT2i unless contraindicated.
5. Nephrology Imperatives (eGFR Cutoffs)
6. India-Specific Pearls
💡 Saroglitazar (India’s Own Molecule): Dual PPAR-alpha/gamma agonist developed by Zydus (India). 4 mg OD. Approved for diabetic dyslipidaemia and NASH. Reduces TG 40-50%, raises HDL, reduces hepatic fat. Unlike Pioglitazone, does NOT cause oedema or significant weight gain.
💡 Voglibose for Rice-Eating India: AGIs are uniquely suited to the Indian carbohydrate-heavy diet. Voglibose 0.2-0.3 mg before meals blunts PPG spikes by 40-60 mg/dL. RSSDI-endorsed for prediabetes prevention.
💡 Teneligliptin: Most prescribed DPP-4i in India (₹3-5/tablet at Jan Aushadhi Kendras). No renal dose adjustment at any eGFR. Available in FDCs with Metformin. Not US-FDA approved but has extensive Japanese/Indian post-marketing data.
7. Sick-Day Rules (Teach Every Patient)
During acute illness, vomiting, or reduced oral intake:
STOP: Metformin (lactic acidosis), SGLT2i (euglycaemic DKA), Diuretics (dehydration).
CONTINUE: DPP-4i, Insulin (may need to increase).
REDUCE: SU (halve dose or skip if not eating).
MONITOR: Blood glucose every 4-6 hours. Seek help if glucose > 300, persistent vomiting, or ketonuria.
HYDRATE: Small frequent sips of ORS or clear fluids, 150-200 mL per hour.
8. Common Indian FDCs (Fixed Dose Combinations)
